title: A single-arm clinical study of continuous usage of bevacizumab as second-line chemotherapy for Chinese patients with metastatic colorectal cancer.
abstract: Recent studies demonstrated that second-line chemotherapy of continuous usage of bevacizumab after initial disease progression improved survivals in Caucasian patients with metastatic colorectal cancer (mCRC). We intended to examine this strategy in Chinese patients specifically. Eligible Chinese mCRC patients had disease progression up to 3 months after receiving first-line bevacizumab-included chemotherapy. They were given IV bevacizumab infusion at 5 mg/kg on day 1 every 2 weeks. The primary endpoint is progression-free survival (PFS). One hundred and fourteen eligible patients received second-line chemotherapy plus bevacizumab. Among them, 56.1 % were male patients and median age was 63.4 years (29-81 years). Median follow-up time is 12 months. Median PFS was 7.3 months (95 % CI 3.9-8.9 months), and median OS was 14.7 months (95 % CI 10.7-18.5 months). No patients had complete responses, but 17 patients had partial response and 75 had stable disease. The safety profiles showed that severe adverse events (grades 3-4), such as nausea, proteinuria and hypertension, were often experienced by Chinese mCRC patients received continuous second-line chemotherapy of bevacizumab. Continuous usage of bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer in China showed equivalent improvement on patients' survival as Caucasian counterparts.
authors.affiliation: The Department of Gastrointestinal Surgery, First Affiliated Hospital of Zhengzhou University, 1 Jianshe East Rd, Zhengzhou, 450052, Henan Province, China, guojun.wang@aol.com.
authors.forename: Guojun
authors.initials: G
authors.lastname: Wang
authors.forename: Yanwei
authors.initials: Y
authors.lastname: Ye
authors.forename: Xiefu
authors.initials: X
authors.lastname: Zhang
authors.forename: Hongxiang
authors.initials: H
authors.lastname: Liu
authors.forename: Junmin
authors.initials: J
authors.lastname: Song
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D044466:Asian People; D000068258:Bevacizumab / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D000068258:Bevacizumab